Nucana (NCNA) has released an update.
NuCana plc showcased positive results from its Phase 2 study of NUC-7738 in combination with pembrolizumab, offering hope for metastatic melanoma patients who have not responded to PD-1 inhibitor therapy. The treatment led to prolonged progression-free survival and disease control in 75% of participants, demonstrating a potential new therapeutic avenue for resistant melanoma cases. With a favorable safety profile, the dual therapy could redefine the standard of care for this challenging patient demographic.
For further insights into NCNA stock, check out TipRanks’ Stock Analysis page.
